103 related articles for article (PubMed ID: 24935032)
1. In vitro analysis of the susceptibility of HIV-1 subtype A and CRF01_AE integrases to raltegravir.
Bellecave P; Malato L; Calmels C; Reigadas S; Parissi V; Andreola ML; Fleury H
Int J Antimicrob Agents; 2014 Aug; 44(2):168-72. PubMed ID: 24935032
[TBL] [Abstract][Full Text] [Related]
2. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Nguyen HL; Ruxrungtham K; Delaugerre C
Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
[TBL] [Abstract][Full Text] [Related]
3. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
4. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.
Brenner BG; Lowe M; Moisi D; Hardy I; Gagnon S; Charest H; Baril JG; Wainberg MA; Roger M
J Med Virol; 2011 May; 83(5):751-9. PubMed ID: 21360548
[TBL] [Abstract][Full Text] [Related]
5. In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
Charpentier C; Bertine M; Visseaux B; Leleu J; Larrouy L; Peytavin G; Mourez T; Collin G; Brun-Vézinet F; Plantier JC; Descamps D
AIDS; 2013 Nov; 27(18):2959-61. PubMed ID: 23942060
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.
Nguyen HL; Charpentier C; Nguyen N; de Truchis P; Molina JM; Ruxrungtham K; Delaugerre C
HIV Med; 2013 Feb; 14(2):85-91. PubMed ID: 22994529
[TBL] [Abstract][Full Text] [Related]
7. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.
Pollicita M; Surdo M; Di Santo F; Cortese MF; Fabeni L; Fedele V; Malet I; Marcelin AG; Calvez V; Ceccherini-Silberstein F; Perno CF; Svicher V
J Antimicrob Chemother; 2014 Sep; 69(9):2412-9. PubMed ID: 24860155
[TBL] [Abstract][Full Text] [Related]
8. Appearance of Drug Resistance-Associated Mutations in Human Immunodeficiency Virus Type 1 CRF01_AE Integrase Derived from Drug-Naive Thai Patients.
Isarangkura-Na-Ayuthaya P; Kaewnoo W; Auwanit W; de Silva UC; Ikuta K; Sawanpanyalert P; Kameoka M
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1341-3. PubMed ID: 20836708
[TBL] [Abstract][Full Text] [Related]
9. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.
Bar-Magen T; Sloan RD; Faltenbacher VH; Donahue DA; Kuhl BD; Oliveira M; Xu H; Wainberg MA
Retrovirology; 2009 Nov; 6():103. PubMed ID: 19906306
[TBL] [Abstract][Full Text] [Related]
10. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.
Neogi U; Singh K; Aralaguppe SG; Rogers LC; Njenda DT; Sarafianos SG; Hejdeman B; Sönnerborg A
AIDS; 2018 Feb; 32(4):469-476. PubMed ID: 29239896
[TBL] [Abstract][Full Text] [Related]
11. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong.
Yam WC; Chen JH; Wong KH; Chan K; Cheng VC; Lam HY; Lee SS; Zheng BJ; Yuen KY
J Clin Virol; 2006 Apr; 35(4):454-7. PubMed ID: 16386461
[TBL] [Abstract][Full Text] [Related]
13. Improvement of the oligonucleotide ligation assay for detection of the M184V drug-resistant mutation in patients infected with human immunodeficiency virus type 1 subtype CRF01_AE.
Dokuta S; Utaipat U; Praparattanapan J; Keitkarn J; Maneekarn N; Sirisanthana T; Supparatpinyo K
J Virol Methods; 2013 Jun; 190(1-2):20-8. PubMed ID: 23562659
[TBL] [Abstract][Full Text] [Related]
14. Consensus HIV-1 subtype A integrase and its raltegravir-resistant variants: design and characterization of the enzymatic properties.
Shadrina O; Krotova O; Agapkina J; Knyazhanskaya E; Korolev S; Starodubova E; Viklund A; Lukashov V; Magnani M; Medstrand P; Karpov V; Gottikh M; Isaguliants M
Biochimie; 2014 Jul; 102():92-101. PubMed ID: 24594066
[TBL] [Abstract][Full Text] [Related]
15. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
[TBL] [Abstract][Full Text] [Related]
16. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
18. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.
Fransen S; Gupta S; Frantzell A; Petropoulos CJ; Huang W
J Virol; 2012 Jul; 86(13):7249-55. PubMed ID: 22553340
[TBL] [Abstract][Full Text] [Related]
19. Performance comparison of an in-house integrase genotyping assay versus the ViroSeq™ Integra48, and study of HIV-1 integrase polymorphisms in Hong Kong.
To SW; Chen JH; Wong KH; Chan KC; Ng HM; Wu H; Lam JT; Yam WC
J Clin Virol; 2013 Sep; 58(1):299-302. PubMed ID: 23886504
[TBL] [Abstract][Full Text] [Related]
20. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.
Delviks-Frankenberry KA; Nikolenko GN; Maldarelli F; Hase S; Takebe Y; Pathak VK
J Virol; 2009 Sep; 83(17):8502-13. PubMed ID: 19553318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]